Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
The options carry an exercise price equal to the grant-date closing price and vest subject to continued employment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apnimed (APMD) granted stock options covering 481,300 shares to new non-executive employees on October 1, 2026, as employment inducements.
The awards went to 19 employees under the 2026 Inducement Plan. Each option has an exercise price of $22.54 per share, equal to the closing trading price on the grant date. One-fourth vests on the first anniversary of each employee’s start date, with equal monthly installments over the next three years, subject to continued employment. The compensation committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4).
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Options covering 481,300 shares at $22.54 per share create potential dilution if exercised.
Key Figures
- Employees granted options
- 19 employees
- New non-executive employees
- Aggregate options
- 481,300 shares
- Granted under the 2026 Inducement Plan
- Exercise price
- $22.54 per share
- Equal to the closing trading price on the grant date
- Vesting schedule
- One-fourth at the first anniversary, then equal monthly installments for 3 years
- Subject to continued employment
Historical Context
-
Prior 2026 Inducement Plan award covered 10 employees and 428,428 options at $26.85.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed’s board of directors granted 19 new non-executive employees non-qualified stock options to purchase an aggregate of 481,300 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of
The above-described awards were granted as an inducement material to such employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by Apnimed’s board of directors on August 21, 2026.
About Apnimed, Inc.
Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Apnimed believes the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with obstructive sleep apnea (“OSA”). Apnimed believes that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA’s disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment and help more people get the oxygen and restorative sleep needed to thrive.
Apnimed is advancing its product candidate, AD109, designed to improve oxygenation in individuals living with OSA. Apnimed believes that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed’s New Drug Application for AD109 was assigned a Prescription Drug User Fee Act goal date of February 28, 2027.
Visit us at Apnimed.com and follow us on LinkedIn and X
Cautionary Note Regarding Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Apnimed’s expectations as to our commercial readiness, the clinical and therapeutic potential of AD109 (including to address OSA), and the occurrence and timing of the PDUFA goal date for AD109.
Forward-looking statements are based on Apnimed’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in biopharmaceutical product development. These and other risks and uncertainties are described more fully in the sections titled “Risk Factors” of the final prospectus related to the offering filed with the SEC and in its most recent periodic report filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Apnimed undertakes no duty to update such information except as required under applicable law.
Media Contact:
media@apnimed.com
Investor Contact:
ir@apnimed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did Apnimed grant to new employees on October 1, 2026?
Apnimed granted 19 new non-executive employees options to purchase an aggregate of 481,300 common shares. The exercise price is $22.54 per share, equal to the company’s closing trading price on the grant date.
When do Apnimed’s October 2026 employee inducement options vest?
One-fourth of the shares underlying each employee’s options vest on the first anniversary of that employee’s start date. The remainder vests in equal monthly installments over the next three years, subject to continued employment on each vesting date.